# Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery

> **NCT07032792** · PHASE2 · RECRUITING · sponsor: **Northwell Health** · enrollment: 140 (estimated)

## Conditions studied

- Cardiac Disease
- Surgery
- Bleeding

## Interventions

- **DRUG:** FEIBA
- **DRUG:** FFP

## Key facts

- **NCT ID:** NCT07032792
- **Lead sponsor:** Northwell Health
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-11-03
- **Primary completion:** 2028-11
- **Final completion:** 2029-11
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07032792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07032792, "Factor VIII Inhibitor Bypass Activity (FEIBA) Versus Fresh Frozen Plasma As First Line Therapy For Bleeding After Cardiac Surgery". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07032792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*